BeiGene (NASDAQ:BGNE) Stock Price Up 3.3%

BeiGene, Ltd. (NASDAQ:BGNEGet Free Report) shares traded up 3.3% during mid-day trading on Tuesday . The stock traded as high as $151.00 and last traded at $151.00. 13,883 shares changed hands during trading, a decline of 94% from the average session volume of 237,531 shares. The stock had previously closed at $146.24.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Guggenheim reduced their price objective on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. TD Cowen upped their price objective on BeiGene from $236.00 to $254.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. JPMorgan Chase & Co. raised their target price on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Bank of America decreased their price target on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research note on Monday, April 8th. Finally, Sanford C. Bernstein cut their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a report on Wednesday, March 27th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, BeiGene presently has an average rating of “Moderate Buy” and an average price target of $251.93.

Read Our Latest Research Report on BeiGene

BeiGene Stock Performance

The stock has a market capitalization of $15.22 billion, a price-to-earnings ratio of -21.01 and a beta of 0.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.08 and a quick ratio of 1.84. The stock has a 50-day moving average of $153.58 and a 200 day moving average of $162.90.

BeiGene (NASDAQ:BGNEGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.07) by $0.66. The business had revenue of $751.70 million during the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative net margin of 28.39% and a negative return on equity of 21.70%. BeiGene’s revenue for the quarter was up 67.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.34) earnings per share. On average, analysts expect that BeiGene, Ltd. will post -8.2 EPS for the current year.

Insiders Place Their Bets

In related news, CEO John Oyler sold 26,716 shares of BeiGene stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the transaction, the chief executive officer now owns 12,084 shares of the company’s stock, valued at approximately $1,799,186.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.43% of the company’s stock.

Institutional Trading of BeiGene

Several hedge funds have recently bought and sold shares of the stock. Capital International Investors lifted its position in BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after acquiring an additional 727,556 shares in the last quarter. Baillie Gifford & Co. raised its position in BeiGene by 17.9% in the 3rd quarter. Baillie Gifford & Co. now owns 3,871,598 shares of the company’s stock valued at $696,384,000 after buying an additional 588,294 shares during the last quarter. FMR LLC boosted its position in BeiGene by 3.0% during the 3rd quarter. FMR LLC now owns 2,352,730 shares of the company’s stock worth $423,186,000 after acquiring an additional 69,297 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of BeiGene by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock worth $316,862,000 after acquiring an additional 117,905 shares in the last quarter. Finally, Capital International Inc. CA raised its holdings in shares of BeiGene by 6.0% in the first quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock valued at $134,240,000 after purchasing an additional 48,615 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

About BeiGene

(Get Free Report)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.

Featured Stories

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.